Vizsgálati helyszín
UNC Health Cancer Care Raleigh
Raleigh, North Carolina 27607, Egyesült ÁllamokMég nincs intézményhez kötve
- 14futó vizsgálat
- 3lezárt vizsgálat
Az itteni vizsgálatok
Miről szól a helyszín 17 vizsgálata, a regiszteri adatlapjaik szerint.
- Fázis
- 3. fázis12 vizsgálat
- 2/3. fázis3 vizsgálat
- 2. fázis1 vizsgálat
- Állapot
- Fut, nem toboroz10 vizsgálat
- Toboroz4 vizsgálat
- Lezárult3 vizsgálat
- Fő szponzor
- NRG Oncology7 vizsgálat
- National Cancer Institute (NCI)6 vizsgálat
- Alliance for Clinical Trials in Oncology2 vizsgálat
- SWOG Cancer Research Network2 vizsgálat
Futó vizsgálatok
Toboroz
Testing Shorter Duration Radiation Therapy Versus the Usual Radiation Therapy in Patients Receiving the Usual Chemotherapy Treatment for Bladder Cancer, ARCHER Study
NCT07097142· 3. fázis· NRG Oncology· Forrás
Contact: Michael C. Repka (principal investigator)
Toboroz
Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25
NCT05879926· 3. fázis· NRG Oncology· Forrás
Contact: Elizabeth C. Dees (principal investigator)
Toboroz
Pembrolizumab vs. Observation in People With Triple-negative Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Pembrolizumab
NCT05812807· 3. fázis· Alliance for Clinical Trials in Oncology· Forrás
Contact: Yara Abdou (principal investigator)
Toboroz
Comparing Combinations of Targeted Drugs for Advanced Non-Small Cell Lung Cancer That Has EGFR and MET Gene Changes (A Lung-MAP Treatment Trial)
NCT05642572· 2. fázis· SWOG Cancer Research Network· Forrás
Toboroz
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
NCT05334069· Alliance for Clinical Trials in Oncology· Forrás
Contact: Marie Wood, MD
Toboroz
Colon Adjuvant Chemotherapy Based on Evaluation of Residual Disease
NCT05174169· 2/3. fázis· NRG Oncology· Forrás
Contact: Ranjit Joseph (principal investigator)
Fut, nem toboroz
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NCT05050084· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NCT04513717· 3. fázis· NRG Oncology· Forrás
Fut, nem toboroz
Testing the Addition of the Drug Atezolizumab to the Usual Radiation Treatment for Patients With Early Non-small Cell Lung Cancer
NCT04214262· 3. fázis· National Cancer Institute (NCI)· Forrás
Toboroz
Lung-MAP: A Master Screening Protocol for Previously-Treated Non-Small Cell Lung Cancer
NCT03851445· 2/3. fázis· SWOG Cancer Research Network· Forrás
Contact: Jennifer Beeler
Fut, nem toboroz
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer
NCT03233711· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Nivolumab in Treating Patients With Localized Kidney Cancer Undergoing Nephrectomy
NCT03055013· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia
NCT00843882· 3. fázis· National Cancer Institute (NCI)· Forrás
Fut, nem toboroz
Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple Myeloma
NCT00602641· 3. fázis· National Cancer Institute (NCI)· Forrás
Egyszerre toboroz
Hány vizsgálat toboroz itt egyszerre ugyanarra az indikációra. Darabszám, nem értékelés.
Hibát jelzek